Clovis signs radiopharmaceuticals R&D deal with German biotech 3BClovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with Share XClovis signs radiopharmaceuticals R&D deal with German biotech 3Bhttps://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/
Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
